Strategies for Accelerated CMC Development

The “need for speed” that drove pharmaceutical developers during the pandemic is no longer a one-off phenomenon; it is increasingly becoming business as usual. This shift is reflected in the industry’s demand for accelerated processes for chemistry, manufacturing, and controls (CMC) development. Given the risks implied by this market-driven acceleration, potential partnerships with contract development and manufacturing organizations (CDMOs) must be thoroughly vetted.